Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

clinical trial

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT02137850

P6099clinical trial phasephase III clinical trialQ42824827
P17countryCanadaQ16
JapanQ17
United States of AmericaQ30
SpainQ29
ItalyQ38
AustriaQ40
GreeceQ41
FranceQ142
GermanyQ183
RomaniaQ218
BulgariaQ219
AlgeriaQ262
AustraliaQ408
ArgentinaQ414
IsraelQ801
MalaysiaQ833
TaiwanQ865
ThailandQ869
P582end time2021-11-13
P4135maximum age6
P1050medical conditionhemophilia AQ2092064
P1132number of participants125
P6153research siteNovo NordiskQ818846
P1813short namepathfinder™6
P580start time2014-06-26
P8363study typeinterventional studyQ78089383
P1476titleAn Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A

Search more.